CINC
Price:
$29.06
Market Cap:
$1.27B
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Industry
Biotechnology
IPO Date
2022-01-07
Stock Exchange
NASDAQ
Ticker
CINC
According to CinCor Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -14.46. This represents a change of 54.86% compared to the average of -9.34 of the last 4 quarters.
The mean historical PE Ratio of CinCor Pharma, Inc. over the last ten years is -34.78. The current -14.46 PE Ratio has changed 4.06% with respect to the historical average. Over the past ten years (40 quarters), CINC's PE Ratio was at its highest in in the December 2021 quarter at -4.24. The PE Ratio was at its lowest in in the March 2021 quarter at -24.47.
Average
-34.78
Median
-16.89
Minimum
-76.19
Maximum
-11.26
Discovering the peaks and valleys of CinCor Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -11.26
Minimum Annual Increase = -77.84%
Minimum Annual PE Ratio = -76.19
| Year | PE Ratio | Change |
|---|---|---|
| 2021 | -11.26 | -33.34% |
| 2020 | -16.89 | -77.84% |
The current PE Ratio of CinCor Pharma, Inc. (CINC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.78
5-year avg
-34.78
10-year avg
-34.78
CinCor Pharma, Inc.’s PE Ratio is less than CTI BioPharma Corp. (-11.46), less than EQRx, Inc. (5.40), less than POINT Biopharma Global Inc. (12.03), less than VectivBio Holding AG (-7.94), greater than Poseida Therapeutics, Inc. (-82.89), less than Gracell Biotechnologies Inc. (-1.61), less than Ethzilla Corp. (-0.65), less than Verve Therapeutics, Inc. (-5.46), less than Albireo Pharma, Inc. (-5.61),
| Company | PE Ratio | Market cap |
|---|---|---|
| -11.46 | $1.20B | |
| 5.40 | $1.14B | |
| 12.03 | $1.33B | |
| -7.94 | $1.06B | |
| -82.89 | $925.93M | |
| -1.61 | $989.87M | |
| -0.65 | $188.33M | |
| -5.46 | $994.04M | |
| -5.61 | $915.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CinCor Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CinCor Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CinCor Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for CinCor Pharma, Inc. (CINC)?
What is the highest PE Ratio for CinCor Pharma, Inc. (CINC)?
What is the 3-year average PE Ratio for CinCor Pharma, Inc. (CINC)?
What is the 5-year average PE Ratio for CinCor Pharma, Inc. (CINC)?
How does the current PE Ratio for CinCor Pharma, Inc. (CINC) compare to its historical average?